Literature DB >> 3022787

Past, present, and future surgical management of malignant epithelial neoplasms of the lacrimal gland.

J W Henderson.   

Abstract

Entities:  

Mesh:

Year:  1986        PMID: 3022787      PMCID: PMC1040816          DOI: 10.1136/bjo.70.10.727

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


× No keyword cloud information.
  6 in total

1.  BONE RESECTION IN THE EXCISION OF EPITHELIAL TUMORS OF THE LACRIMAL GLAND.

Authors:  A B REESE; I S JONES
Journal:  Arch Ophthalmol       Date:  1964-03

2.  Epithelial lacrimal gland tumors: pathology as a guide to prognosis.

Authors:  A W FORREST
Journal:  Trans Am Acad Ophthalmol Otolaryngol       Date:  1954 Nov-Dec

3.  Combined therapeutic approach to malignant lacrimal gland tumors.

Authors:  R M Byers; R G Berkeley; M Luna; R H Jesse
Journal:  Am J Ophthalmol       Date:  1975-01       Impact factor: 5.258

4.  Regional cranio-orbital resection for recurrent tumors with delayed reconstruction.

Authors:  J E Murray; D D Matson; M B Habal; G W Geelhoed
Journal:  Surg Gynecol Obstet       Date:  1972-03

5.  En bloc removal of intrinsic neoplasms of the lacrimal gland.

Authors:  J W Henderson; R W Neault
Journal:  Trans Am Ophthalmol Soc       Date:  1976

6.  Factors affecting the survival of patients with lacrimal gland tumours.

Authors:  J E Wright
Journal:  Can J Ophthalmol       Date:  1982-02       Impact factor: 1.882

  6 in total
  2 in total

1.  Clinical and microdissection genotyping analyses of the effect of intra-arterial cytoreductive chemotherapy in the treatment of lacrimal gland adenoid cystic carcinoma.

Authors:  David T Tse
Journal:  Trans Am Ophthalmol Soc       Date:  2005

2.  Neoadjuvant Intra-Arterial Cytoreductive Chemotherapy for Lacrimal Gland Adenoid Cystic Carcinoma: A Long-Term Follow-up Study of a Trimodal Strategy.

Authors:  David T Tse; Pasquale W Benedetto; Brian C Tse; William J Feuer
Journal:  Am J Ophthalmol       Date:  2022-04-02       Impact factor: 5.488

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.